The global ovarian cancer market accounted for USD 3.06 billion in 2023 and is expected to reach at USD 31.31 billion by 2034 with a CAGR of 23.53% during the forecast period 2024-2034. The market will grow as a result of the rising incidence of ovarian cancer, improvements in early detection technologies, targeted therapies and personalized medicine, regulatory initiatives and incentives, and patient advocacy and awareness campaigns.
One of the deadliest gynecological cancers, ovarian cancer has been increasing in frequency throughout the world. This increase is caused by several factors, including changing lifestyles, aging populations, and environmental exposures. The demand for efficient therapies and diagnostics is rising as more instances are identified. Patients with ovarian cancer have far better prognoses and survival rates when the disease is discovered early. Early diagnosis and intervention are made possible by developments in imaging technologies, including MRI, CT, and ultrasound scans, as well as by the creation of novel biomarkers and genetic testing. For instance, AstraZeneca published encouraging outcomes in February 2024 from the Phase III PAOLA-1 study, which assessed Lynparza (olaparib) plus bevacizumab as a therapy for advanced ovarian cancer.
By type, the epithelial tumors segment accounted for the highest revenue-grossing segment in the global ovarian cancer market in 2023 owing to the high prevalence of epithelial ovarian cancer cases and the established standard of care involving surgery and chemotherapy for this subtype. For instance, in January 2024, Roche declared that the FDA had approved the combination of chemotherapy and Avastin (bevacizumab) for the treatment of advanced ovarian cancer. Additionally, the germ cell tumors segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing interest in personalized medicine approaches targeting specific genetic mutations associated with germ cell tumors, leading to the development of novel targeted therapies and improved treatment outcomes.
By diagnosis, the computed tomography (CT) scans segment accounted for the highest revenue-grossing segment in the global ovarian cancer market in 2023 owing to the high utilization of CT scans for initial assessment, staging, and treatment planning in ovarian cancer patients, supported by their widespread availability, cost-effectiveness, and ability to provide detailed imaging of the abdomen and pelvis. For instance, Johnson & Johnson reported encouraging Phase III findings for niraparib in the PRIMA trial in December 2023, demonstrating a noteworthy improvement in patients' progression-free survival when dealing with ovarian cancer. Additionally, the magnetic resonance imaging (MRI) scans segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing demand for MRI scans due to their superior soft tissue contrast, multiplanar imaging capabilities, and increasing utilization for evaluating tumor extent, detecting metastases, and assessing treatment response in ovarian cancer patients.
By treatment, the chemotherapy segment accounted for the highest revenue-grossing segment in the global ovarian cancer market in 2023 owing to the established role of chemotherapy as the mainstay of ovarian cancer treatment, encompassing both adjuvant and neoadjuvant settings, and its widespread use across different stages and subtypes of the disease. For instance, Merck reported in October 2023 that the FDA had given Keytruda (pembrolizumab) expedited approval for the treatment of advanced or recurrent ovarian cancer. Additionally, the targeted therapy segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of targeted therapies, particularly PARP inhibitors, for ovarian cancer treatment, driven by their efficacy in patients with specific genetic mutations and their expanding indications in maintenance therapy settings.
By end-user, the hospitals segment accounted for the highest revenue-grossing segment in the global ovarian cancer market in 2023 owing to the comprehensive multidisciplinary care provided by hospitals, including surgical intervention, chemotherapy, radiation therapy, and supportive care, making them the primary destination for ovarian cancer diagnosis and treatment. For instance, Bristol Myers Squibb reported encouraging outcomes in November 2023 from the Phase III ATHENA study, which assessed Opdivo (nivolumab) plus chemotherapy in the treatment of advanced ovarian cancer. Additionally, the diagnostic centers segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for specialized imaging and diagnostic services, including MRI and PET scans, for accurate staging, monitoring, and personalized treatment planning in ovarian cancer patients.
North American region is anticipated to have the highest revenue share during the forecast period owing to the advanced healthcare infrastructure, high incidence rates of ovarian cancer, early adoption of novel therapies and diagnostic technologies, and robust research and development activities in the region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising awareness about ovarian cancer, improving access to healthcare services, expanding pharmaceutical markets, increasing research collaborations, and clinical trials in countries like China and India. For instance, GSK reported in March 2024 that Zejula (niraparib) had received FDA approval as a first-line maintenance treatment for advanced ovarian cancer.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
One of the deadliest gynecological cancers, ovarian cancer has been increasing in frequency throughout the world. This increase is caused by several factors, including changing lifestyles, aging populations, and environmental exposures. The demand for efficient therapies and diagnostics is rising as more instances are identified. Patients with ovarian cancer have far better prognoses and survival rates when the disease is discovered early. Early diagnosis and intervention are made possible by developments in imaging technologies, including MRI, CT, and ultrasound scans, as well as by the creation of novel biomarkers and genetic testing. For instance, AstraZeneca published encouraging outcomes in February 2024 from the Phase III PAOLA-1 study, which assessed Lynparza (olaparib) plus bevacizumab as a therapy for advanced ovarian cancer.
By type, the epithelial tumors segment accounted for the highest revenue-grossing segment in the global ovarian cancer market in 2023 owing to the high prevalence of epithelial ovarian cancer cases and the established standard of care involving surgery and chemotherapy for this subtype. For instance, in January 2024, Roche declared that the FDA had approved the combination of chemotherapy and Avastin (bevacizumab) for the treatment of advanced ovarian cancer. Additionally, the germ cell tumors segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing interest in personalized medicine approaches targeting specific genetic mutations associated with germ cell tumors, leading to the development of novel targeted therapies and improved treatment outcomes.
By diagnosis, the computed tomography (CT) scans segment accounted for the highest revenue-grossing segment in the global ovarian cancer market in 2023 owing to the high utilization of CT scans for initial assessment, staging, and treatment planning in ovarian cancer patients, supported by their widespread availability, cost-effectiveness, and ability to provide detailed imaging of the abdomen and pelvis. For instance, Johnson & Johnson reported encouraging Phase III findings for niraparib in the PRIMA trial in December 2023, demonstrating a noteworthy improvement in patients' progression-free survival when dealing with ovarian cancer. Additionally, the magnetic resonance imaging (MRI) scans segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing demand for MRI scans due to their superior soft tissue contrast, multiplanar imaging capabilities, and increasing utilization for evaluating tumor extent, detecting metastases, and assessing treatment response in ovarian cancer patients.
By treatment, the chemotherapy segment accounted for the highest revenue-grossing segment in the global ovarian cancer market in 2023 owing to the established role of chemotherapy as the mainstay of ovarian cancer treatment, encompassing both adjuvant and neoadjuvant settings, and its widespread use across different stages and subtypes of the disease. For instance, Merck reported in October 2023 that the FDA had given Keytruda (pembrolizumab) expedited approval for the treatment of advanced or recurrent ovarian cancer. Additionally, the targeted therapy segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of targeted therapies, particularly PARP inhibitors, for ovarian cancer treatment, driven by their efficacy in patients with specific genetic mutations and their expanding indications in maintenance therapy settings.
By end-user, the hospitals segment accounted for the highest revenue-grossing segment in the global ovarian cancer market in 2023 owing to the comprehensive multidisciplinary care provided by hospitals, including surgical intervention, chemotherapy, radiation therapy, and supportive care, making them the primary destination for ovarian cancer diagnosis and treatment. For instance, Bristol Myers Squibb reported encouraging outcomes in November 2023 from the Phase III ATHENA study, which assessed Opdivo (nivolumab) plus chemotherapy in the treatment of advanced ovarian cancer. Additionally, the diagnostic centers segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for specialized imaging and diagnostic services, including MRI and PET scans, for accurate staging, monitoring, and personalized treatment planning in ovarian cancer patients.
North American region is anticipated to have the highest revenue share during the forecast period owing to the advanced healthcare infrastructure, high incidence rates of ovarian cancer, early adoption of novel therapies and diagnostic technologies, and robust research and development activities in the region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising awareness about ovarian cancer, improving access to healthcare services, expanding pharmaceutical markets, increasing research collaborations, and clinical trials in countries like China and India. For instance, GSK reported in March 2024 that Zejula (niraparib) had received FDA approval as a first-line maintenance treatment for advanced ovarian cancer.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Type, Diagnosis, Treatment, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement
Segmentation: Ovarian Cancer Market Report 2023 - 2034
Ovarian Cancer Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Epithelial Tumors
- Germ Cell Tumors
- Stromal Tumors
- Primary Peritoneal Cancer
Ovarian Cancer Market Analysis & Forecast by Diagnosis 2023 - 2034 (Revenue USD Bn)
- Computed Tomography (C.T.) Scans
- Ultrasound
- Barium Enema X-Ray
- Magnetic Resonance Imaging (MRI) Scans
- Chest X-ray
- Positron Emission Tomography (PET) Scan
- Other Diagnostic Tests
Ovarian Cancer Market Analysis & Forecast by Treatment 2023 - 2034 (Revenue USD Bn)
- Chemotherapy
- Radiation Therapy
- Targeted Therapy
- Hormone Therapy
- Other Therapeutic Treatments
- Surgery
Ovarian Cancer Market Analysis & Forecast by End-User2023 - 2034 (Revenue USD Bn)
- Hospitals
- Diagnostic Centers
- Drug Stores
- Online Pharmacies
- Others
Ovarian Cancer Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Ovarian Cancer Market: Type Estimates & Trend Analysis
8. Ovarian Cancer Market: Diagnosis Estimates & Trend Analysis
9. Ovarian Cancer Market: Treatment Estimates & Trend Analysis
10. Ovarian Cancer Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Ovarian Cancer Market
13. Europe Global Ovarian Cancer Market
14. Asia Pacific Global Ovarian Cancer Market
15. Latin America Global Ovarian Cancer Market
16. MEA Global Ovarian Cancer Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- AstraZeneca
- Roche Holdings
- Johnson & Johnson
- Merck & Co. Inc.
- Bristol Myers Squibb
- GlaxoSmithKline plc
- Pfizer Inc.
- AbbVie Inc.
- Novartis AG
- Eisai Co. Ltd.
- TESARO (a GSK company)
- Clovis Oncology
- Genentech Inc. (a member of the Roche Group)
- Takeda Pharmaceutical Company Limited
- Amgen Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | October 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 3.06 Billion |
| Forecasted Market Value ( USD | $ 31.31 Billion |
| Compound Annual Growth Rate | 23.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
